Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Suceagu – page 15

447 clinical trials in Suceagu, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Suceagu at a glance
447
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

447 trials in Suceagu

Open in trial search

Study on the Use of Simoctocog Alfa for Women and Girls with Hemophilia A Undergoing Surgery

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Simoctocog Alfa
  • Sponsor:Octapharma AG

Migraine+2

Recruiting

Study on Long-term Safety and Tolerability of Atogepant for Children and Teens (Ages 6-17) with Migraine

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Namodenoson Treatment in Patients with Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Namodenoson
  • Sponsor:Can-Fite Biopharma Ltd.

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Phase 3 Study of Ivonescimab Versus Durvalumab as Consolidation Therapy in Patients with Unresectable Stage III Non‑Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Summit Therapeutics Inc.

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Small cell lung cancer+2

Not yet recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

Study of Two Doses of EXPD-101 vs Placebo for Reducing COPD Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:EXPD-101
  • Sponsor:Expedition Therapeutics Inc.

Type 2 diabetes mellitus+2

Not yet recruiting

Efficacy and Safety of Olatorepatide in Adults with Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Asthma

Not yet recruiting

Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Chiesi Farmaceutici S.p.A.

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Carcinoid syndrome

Not yet recruiting

Efficacy and Safety Study of Paltusotine for Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Paltusotine
  • Sponsor:Crinetics Pharmaceuticals Inc.

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Suceagu

What the registry says about research in the country

01 Female Urogenital Diseases and Pregnancy Complications

In Suceagu, clinical research in female urogenital diseases is focused on improving care for stress urinary incontinence. The trials are looking at whether new treatment approaches can better reduce symptoms and support daily comfort for women living with this condition.

  • Stress urinary incontinence
  • Female urogenital health
  • Symptom control and quality of life
  • Evaluating a new therapy approach

This area reflects a practical effort to find more effective options for a common and often disruptive condition.

02 Neoplasms

Cancer research in this city includes studies in non-small cell lung cancer, with attention on patients who have HER2 mutations. The work is aimed at determining whether a targeted treatment can improve outcomes compared with standard care after surgery.

  • Non-small cell lung cancer
  • HER2-mutated tumors
  • Post-surgical cancer care
  • Testing treatment effectiveness

This field highlights efforts to advance more precise cancer treatment strategies and strengthen long-term disease control.

03 Metabolic and Urologic Symptom Research

Another active focus combines obesity or overweight with urinary incontinence, reflecting interest in how weight-related health issues may affect urinary symptoms. The research is designed to see whether a new therapy can better improve patient-reported outcomes.

  • Obesity and overweight
  • Urinary incontinence
  • Women’s health
  • Improving symptom outcomes

These studies bring together metabolic and urologic care in a way that may help guide more personalized treatment.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.